Study to Assess the Management of Synthetic Disease-modifying Antirheumatic Drug (DMARD) at the Onset of Adverse Events, Intolerance or Lack of Efficacy in Rheumatoid Arthritis (RA)
NCT02094326
·
clinicaltrials.gov ↗
COMPLETED
Status
301
Enrollment
OTHER
Sponsor class
Conditions
Rheumatoid Arthritis
Sponsor
Fundación Andaluza de Reumatología